Trial did not meet primary efficacy end point of disease-free survival in patients with localized RCC at high risk for postnephrectomy relapse.
The PFS benefit was driven primarily by patients with intermediate-risk disease.
Among patients with a variety of solid tumors, investigators found favorable associations of immune checkpoint inhibitor therapy with quality of life compared with no immunotherapy use.
Serum sodium levels in the lower end of the normal range are associated with inferior outcomes in metastatic renal cell carcinoma, a study suggests.
An accurate estimate of future GFR after nephrectomy would help to guide operative strategy and use of adjuvant or neoadjuvant therapies, according to a recent editorial.